Renhuang Pharmaceuticals, Inc has recently been rated as ‘Sector Outperform’ by Beacon Equity Research; and thus, a target price of $7.00 has also been issued.
Renhuang Pharmaceuticals is a leading company focused on manufacturing and distributing a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products in mainland China. The company’s three major product lines consist of: Acanthopanax-based natural medicinal products, the Shark Power healthcare series, and traditional Chinese medicines.
Renhuang, since their initial formation, has been able to successfully establish a leading research and development infrastructure that consists of in-house researchers, a post-doctoral working center, and collaborations with leading institutions and scientists. The Company currently has a portfolio of over 100 products and a presence in more than 50 markets, with much more room for further corporate expansion.
Through various acquisitions, the company is able to expand their global presence directly. Such acquisitions have included Qingyang Pharmaceutical Co. Ltd and Dongfanghong Pharmaceutical Co. The acquisition of Qingyang was momentous for the company, as they were able to process 18,000 tons of herbal raw materials into extracts on a monthly basis. The 2003 acquisition of Dongfanghong Pharmaceutical Co was also critical as Renhuang was able to control over 70% of China’s Acanthopanax resource.
Let us hear your thoughts below:
